These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22292313)

  • 1. [How to optimize biopharmaceutical treatment safety?].
    Prugnaud JL
    Bull Acad Natl Med; 2011 Mar; 195(3):679-95; discussion 695-8. PubMed ID: 22292313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economics of market access for biopharmaceuticals and biosimilars.
    Simoens S
    J Med Econ; 2009 Sep; 12(3):211-8. PubMed ID: 19723019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietins, biosimilars and immunogenicity.
    Schellekens H
    J Nephrol; 2008; 21(4):497-502. PubMed ID: 18651538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulatory framework of biosimilars in the European Union.
    Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
    Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: the 'future' of biologic therapy?
    Ranjan N; Mahajan VK; Misra M
    J Dermatolog Treat; 2011 Dec; 22(6):319-22. PubMed ID: 20666673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-on biologics: challenges of the "next generation".
    Schellekens H
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative testing and pharmacovigilance of biosimilars.
    Locatelli F; Roger S
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars--global issues, national solutions.
    Knezevic I; Griffiths E
    Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.
    van Beers MM; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1473-84. PubMed ID: 23027660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled biopharmaceutical drug development: nonclinical considerations and case studies.
    McElroy MC; Kirton C; Gliddon D; Wolff RK
    Inhal Toxicol; 2013 Mar; 25(4):219-32. PubMed ID: 23480198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.
    Patten PA; Schellekens H
    Dev Biol (Basel); 2003; 112():81-97. PubMed ID: 12762507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Through the looking glass: the protein science of biosimilars.
    Goldsmith D; Kuhlmann M; Covic A
    Clin Exp Nephrol; 2007 Sep; 11(3):191-195. PubMed ID: 17891344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: recent developments.
    Covic A; Kuhlmann MK
    Int Urol Nephrol; 2007; 39(1):261-6. PubMed ID: 17333516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars and regulatory authorities.
    Minghetti P; Rocco P; Del Vecchio L; Locatelli F
    Nephron Clin Pract; 2011; 117(1):c1-7. PubMed ID: 20689318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC; Riggin RM
    Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: it's not as simple as cost alone.
    Roger SD; Goldsmith D
    J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.